Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. 1999

K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
Department of Surgery and Surgical Basic Science, Kyoto University, Japan. kofuji@kuhp.kyoto-u.ac.jp

In this study, we investigated the effect of a novel retinobenzoic acid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), on the growth of 4 human pancreatic-cancer cell lines; BxPC-3, MIAPaCa-2, CFPAC-1 and AsPC-1. TAC-101 significantly inhibited the proliferation of BxPC-3 and MIAPaCa-2 cells in a time- and concentration-dependent manner, but not the proliferation of AsPC-1 cells. Furthermore, the anti-proliferative effects of TAC-101 on BxPC-3 and MIAPaCa-2 cells were stronger than those of all-trans retinoic acid. Flow-cytometric analyses indicated that treatment of BxPC-3 with TAC-101 strongly induces cell-cycle arrest at the G1 phase. The cell-cycle arrest induced by TAC-101 was accompanied by reduction of retinoblastoma-gene product (RB) phosphorylation and an increase of 2 cyclin-dependent kinase (CDK) inhibitors, p21(WAF1/Cip1) (p21) and p27Kip1 (p27). TAC-101 also caused a decrease in cyclin A and thymidylate synthase, which are E2F-regulated gene products. No changes were observed in the expression of cyclin D1, cyclin E on CDK2. In addition, Hoechst staining, gel electrophoresis and flow-cytometric analysis indicated that a marked reduction in the number of BxPC-3 cells with TAC-101 was related to the induction of apoptosis. Our results suggest that TAC-101 inhibits the growth of certain pancreatic-cancer cells by means of G1-phase cell-cycle arrest resulting from the reduction of RB phosphorylation and the up-regulation of p21 and p27 as well as the induction of apoptosis. TAC-101 may therefore be a useful agent for new therapeutic strategies focusing on inhibition of pancreatic-cancer-cell proliferation.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072482 Retinoic Acid Receptor alpha A nuclear receptor protein which belongs to a family of transcription regulators of ligand-responsive regulatory proteins which include steroid hormone receptors. In addition to a C-terminal ligand-binding domain, these nuclear receptors contain a highly-conserved N-terminal zinc-finger domain that mediates binding ligand-responsive elements. RAR alpha 1,RAR alpha 2,Retinoic Acid Receptor alpha 1,Retinoic Acid Receptor alpha 2,alpha 1, RAR,alpha 2, RAR

Related Publications

K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
January 2001, Anticancer research,
K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
January 2005, International journal of gastrointestinal cancer,
K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
November 1996, British journal of cancer,
K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
October 2001, International journal of oncology,
K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
June 2007, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
January 2021, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques,
K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
January 2004, Journal of medicinal food,
K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
January 2017, Evidence-based complementary and alternative medicine : eCAM,
K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
January 2011, International journal of molecular sciences,
K Fujimoto, and R Hosotani, and R Doi, and M Wada, and J U Lee, and T Koshiba, and Y Miyamoto, and S Tsuji, and S Nakajima, and M Imamura
July 2019, Journal of cellular biochemistry,
Copied contents to your clipboard!